To date, US FDA has approved only one small‐molecule drug targeting nonribosomal RNA, which modifies alternative splicing of the survival of motor neuron 2 (SMN2) for the treatment of spinal muscular atrophy (SMA) [16]. This evidence concerns the gene SMN2 and proximal spinal muscular atrophy.